TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Heart protein disease drug tested for Long-Term safety in 700 patients
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety and effectiveness of a drug called vutrisiran in people with a heart condition caused by abnormal protein buildup (ATTR amyloidosis with cardiomyopathy). About 700 adults who were already in related studies will continue or switch to vutri…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 15:12 UTC
-
New shot every 3 months shows promise for rare heart disease
Disease control OngoingThis study tests a drug called vutrisiran in 655 adults with a rare disease that causes heart failure. The drug aims to reduce deaths and heart-related hospital visits. Participants receive an injection every 3 months and are followed for several years.
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS (ATTR) WITH CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:05 UTC